Intended for healthcare professionals

News

HIV: dolutegravir should be preferred treatment option in all populations, says WHO

BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4831 (Published 23 July 2019) Cite this as: BMJ 2019;366:l4831
  1. Gareth Iacobucci
  1. The BMJ

The World Health Organization has recommended that the HIV drug dolutegravir (DTG) be the preferred first line and second line treatment for all populations, after new evidence showed that potential risks to pregnant women and those of childbearing potential is lower than previously thought.

Concerns about a possible link between DTG and neural tube defects in infants born to women using the drug at the …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription